Anti-Somatostatin Receptor 5 抗体 [UMB4] (ab109495)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [UMB4] to Somatostatin Receptor 5
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-Somatostatin Receptor 5 antibody [UMB4]
Somatostatin Receptor 5 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [UMB4] to Somatostatin Receptor 5 -
由来種
Rabbit -
特異性
Internal WB test in PANC-1, human pancreas and human brain lysates indicates this antibody might not detect endogenous Somatostatin Receptor 5. -
アプリケーション
適用あり: WB, IHC-Pmore details
適用なし: Flow Cyt or ICC/IF -
種交差性
交差種: Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: HT29 whole cell lysate (ab3952), 293T (Human embryonic kidney epithelial cell) transfected with human SSTR5 expression vector, IHC-P: Human pancreas
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
UMB4 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab109495の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 39 kDa.
Internal WB test in PANC-1, human pancreas and human brain lysates indicates this antibody might not detect endogenous Somatostatin Receptor 5. |
|
IHC-P |
1/50. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
For unpurified use at 1/100-1/250 |
特記事項 |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 39 kDa. Internal WB test in PANC-1, human pancreas and human brain lysates indicates this antibody might not detect endogenous Somatostatin Receptor 5. |
IHC-P
1/50. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. For unpurified use at 1/100-1/250 |
ターゲット情報
-
機能
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. -
組織特異性
Adult pituitary gland, heart, small intestine, adrenal gland, cerebellum and fetal hypothalamus. No expression in fetal or adult kidney, liver, pancreas, uterus, spleen, lung, thyroid or ovary. -
配列類似性
Belongs to the G-protein coupled receptor 1 family. -
細胞内局在
Cell membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 6755 Human
- Omim: 182455 Human
- SwissProt: P35346 Human
- Unigene: 449840 Human
- Unigene: 728117 Human
-
別名
- SSTR5 antibody
- Somatostatin receptor subtype 5 antibody
- Somatostatin receptor type 5 antibody
see all
画像
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human pancreas tissue sections labeling Somatostatin Receptor 5 with Purified ab109495 at 1:50 dilution (16.3 µg/ml). Heat mediated antigen retrieval was performed with Tris/EDTA buffer (pH 9.0, epitope retrieval solution 2) for 10mins.. Performed on a Leica Biosystems BOND ® RX instrument.was used as the secondary antibody.Negative control:PBS instead of the primary antibody.Hematoxylin was used as a counterstain.
-
Somatostatin receptor 2 (SSTR2), somatostatin receptor 5 (SSTR5) and CXCR4 expression in the hepatoblastoma cell line HepG2 and in the hepatoma cell lines Hep3B and HuH-7 in comparison to the small cell lung cancer cell line NCI-H69 and the neuroendocrine tumor cell line BON-1. Immunohistochemistry (red-brown color), counterstaining with hematoxylin; scale bar: 20 μm. Representative photomicrographs of three independent batches are shown.
HepG2, Hep3B, HuH-7, NCI-H-69, and BON-1 cells (DSMZ, Braunschweig, Germany) were grown in 75 cm2 culture flasks to a confluency of 80%. Cells were washed once with phosphate-buffered saline and transferred into 10% buffered formalin (J.T.Baker, Deventer, The Netherlands) for 2 h. After centrifugation for 10 min at 3500 x g, the supernatant was removed, and 1 ml human pool plasma was added to the cell samples. After brief vortexing, 100 μl human fibrinogen (50–70% protein; ≥80% clottable) was added to each sample, and the samples were vortexed again. The resulting clots were placed for another 24 h in 10% buffered formalin and embedded in paraffin blocks.
(After Kaemmerer, D. et al BMC Cancer. 2017 Dec 28;17(1):896. doi: 10.1186/s12885-017-3911-3).
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)
-
Anti-Somatostatin Receptor 5 antibody [UMB4] (ab109495) at 0.08 µg/ml (purified) + 293T (Human embryonic kidney epithelial cell) transfected with human SSTR5 expression vector, whole cell lysate at 15 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 39 kDa
Blocking and diluting buffer: 5% NFDM/TBST
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (41)
ab109495 は 41 報の論文で使用されています。
- Albani A et al. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr Relat Cancer 29:503-511 (2022). PubMed: 35686696
- Mandriani B et al. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. J Immunother Cancer 10:N/A (2022). PubMed: 35764366
- Saishouji F et al. Ectopic ACTH-producing neuroendocrine tumor occurring with large recurrent metastatic pheochromocytoma: a case report. BMC Endocr Disord 22:184 (2022). PubMed: 35854271
- Viol F et al. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. Cell Oncol (Dordr) 45:1401-1419 (2022). PubMed: 36269546
- Popa O et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 22:1179 (2021). PubMed: 34475969